Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Posted by Emily Schoerning on Jan 17th, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $10.85, for a total transaction of $21,700.00. Following the sale, the president now directly owns 2,911,138 shares in the company, valued at $31,585,847.30. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Songjiang Ma also recently made the following trade(s):

On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.10, for a total value of $565.60.
On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.02, for a total value of $10,591.14.
On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.16, for a total transaction of $9,560.56.
On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.40, for a total transaction of $24,800.00.
On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total value of $25,000.00.
On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.70, for a total value of $25,400.00.
On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.27, for a total value of $24,540.00.
On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total transaction of $21,640.00.
On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Stock Performance

Shares of NASDAQ:GYRE opened at $10.80 on Friday. Gyre Therapeutics, Inc. has a 12-month low of $8.26 and a 12-month high of $26.37. The company’s 50 day moving average price is $11.74 and its two-hundred day moving average price is $12.65.

Hedge Funds Weigh In On Gyre Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. FMR LLC acquired a new stake in shares of Gyre Therapeutics during the 3rd quarter worth $47,000. Barclays PLC boosted its holdings in shares of Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after purchasing an additional 6,855 shares in the last quarter. Rhumbline Advisers bought a new position in shares of Gyre Therapeutics in the 2nd quarter valued at $123,000. Renaissance Technologies LLC bought a new stake in shares of Gyre Therapeutics during the 2nd quarter worth $166,000. Finally, Bank of New York Mellon Corp acquired a new stake in Gyre Therapeutics in the second quarter valued at about $218,000. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.